In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piece de resistance

Executive Summary

HIV resistance testing will soon be the standard of care in the treatment of AIDS, many bet, foremost among them Visible Genetics Inc., Innogenetics NV, PE Biosystems Group and Roche Molecular Systems Inc., all of which are developing genotyping tests to look for genetic mutations in HIV that are known to be resistant to particular drugs. Genotyping is not the only way to assess HIV drug resistance, and two developers of phenotyping resistance tests, ViroLogic Inc. and Virco Group hope to stake a claim in this developing market as well.

You may also be interested in...



Manufacturers Should Map Processes, Bolster Quality Culture To Tackle Data Integrity Problems in The Microbiology Lab

To reduce the opportunity for data integrity failures in the microbiology lab, manufacturers should map out the workflow so that activities and expectations for employees are clearly spelled out. Having formalized processes will ensure that employees don’t cut corners.

EMA Offers Simultaneous Review Of Products For EU And Non-EU Markets

Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.

Europe's COVID-19 Procedures ‘Must Not Be Delayed’

The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel